posted on 2021-10-28, 18:13authored byGabriele Bassi, Nicholas Favalli, Christian Pellegrino, Yuichi Onda, Jörg Scheuermann, Samuele Cazzamalli, Markus G. Manz, Dario Neri
Placental
alkaline phosphatase (PLAP) is an abundant surface antigen
in the malignancies of the female reproductive tract. Nevertheless,
the discovery of PLAP-specific small organic ligands for targeting
applications has been hindered by ligand cross-reactivity with the
ubiquitous tissue non-specific alkaline phosphatase (TNAP). In this
study, we used DNA-encoded chemical libraries to discover a potent
(IC50 = 32 nM) and selective PLAP inhibitor, with no detectable
inhibition of TNAP activity. Subsequently, the PLAP ligand was conjugated
to fluorescein; it specifically bound to PLAP-positive tumors in vitro and targeted cervical cancer in vivo in a mouse model of the disease. Ultimately, the fluorescent derivative
of the PLAP inhibitor functioned as a bispecific engager redirecting
the killing of chimeric antigen receptor-T cells specific to fluorescein
on PLAP-positive tumor cells.